Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis

References

• Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–181.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. New hepatitis C infections nearly tripled over five years [press release] [Internet]. Centers for Disease Control and Prevention web site; 2017 [cited 2020 Jan 14]. Available from: https://www.cdc.gov/nchhstp/newsroom/2017/Hepatitis-Surveillance-Press-Release.html
   Google Scholar
• European Centre for Disease Prevention and Control. Hepatitis C – Annual Epidemiologic Report for 2015. 2017 [cited 2020 Jan 14]. Available from: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2015
   Google Scholar
• Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e1207.
   PubMed Web of Science ®Google Scholar
• Watts T, Stockman L, Martin J, et al. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients – Wisconsin, 2011–2015. Morb Mortal Wkly Rep. 2017;66(42):1136–1139.
   PubMed Web of Science ®Google Scholar
• Ly KN, Jiles RB, Teshale EH, et al. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017;166(11):775–782.
   PubMed Web of Science ®Google Scholar
• Liang TJ, Ward JW. Hepatitis C in injection-drug users – a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169–1171.
   PubMed Web of Science ®Google Scholar
• Zepatier [summary of product characteristics]. Hoddesdon. Hertfordshire, UK: Merck Sharp & Dohme Ltd.; 2018.
   Google Scholar
• Zepatier [prescribing information]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp.; 2018.
   Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane E, Peng CY, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164–168.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–e327.
   PubMed Web of Science ®Google Scholar
• Hezode C, Colombo M, Bourliere M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66(3):736–745.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Kwo PY, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152(6):1372–1382.
   PubMed Web of Science ®Google Scholar
• Asselah T, Reesink H, Gerstoft J, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38(9):1583–1591.
   PubMed Web of Science ®Google Scholar
• Dore GJ, C-EDGE CO-STAR Study Group, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625–634.
   PubMed Web of Science ®Google Scholar
• Feng HP, Guo Z, Caro L, et al. No pharmacokinetic interactions between elbasvir or grazoprevir and methadone in participants receiving maintenance opioid agonist therapy. Clin Transl Sci. 2018;11(6):553–561.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–1086.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.
   PubMed Web of Science ®Google Scholar
• Brown A, Hezode C, Zuckerman E, et al. Efficacy and safety of 12 weeks of elbasvir +/– grazoprevir +/– ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C-SCAPE study. J Viral Hepat. 2018;25(5):457–464.
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2(8):585–594.
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017;52(4):520–533.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Poordad F, Firpi-Morell R, et al. Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and Child–Pugh class B cirrhosis: the C-SALT study. Clin Transl Gastroenterol. 2019;10(4):e00007
   PubMed Web of Science ®Google Scholar
• George J, Burnevich E, Sheen IS, et al. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatol Commun. 2018;2(5):595–606.
   PubMed Web of Science ®Google Scholar
• Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34(1):12–21.
   PubMed Web of Science ®Google Scholar
• Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016;65(6):1112–1119.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53(5):679–688.
   PubMed Web of Science ®Google Scholar
• Lin CY, Sheen IS, Jeng WJ, et al. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. Ann Hepatol. 2013;12(1):62–69.
   PubMed Web of Science ®Google Scholar
• Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112–1119.
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Melazzini M, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection. 2018;46(5):607–615.
   PubMed Web of Science ®Google Scholar
• Trifan A, Stanciu C, Gheorghe L, et al. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine. 2017;96(50):e9271.
   PubMed Web of Science ®Google Scholar
• Hernandez-Conde M, Fernandez I, Perello C, et al. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort. J Viral Hepat. 2019;26(1):55–64.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Akuta N, Sezaki H, et al. Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Hepatol Res. 2019;49(3):256–263.
   PubMed Web of Science ®Google Scholar
• Zarebska-Michaluk D, Jaroszewicz J, Buczynska I, et al. Real-world experience with grazoprevir/elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. J Gastroenterol Hepatol. 2019;2019:4029541.
   Google Scholar
• Abergel A, Asselah T, Mallat A, et al. Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int. 2020. DOI:10.1111/liv.14502
   Web of Science ®Google Scholar
• Asselah T, Pol S, Hezode C, et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: a randomized study. Liver Int. 2020;40(5):1042–1051.
   Web of Science ®Google Scholar